Letter to the editorOmeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma
References (9)
- et al.
Omeprazole, a specific inhibitor of gastric (H+-K+)-ATPase, is a H+-activated oxidizing agent of sulfhydryl groups
J Biol Chem
(1985) - et al.
Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents
J Biol Chem
(1997) - et al.
Efficacy of soluble IL-4 receptor for the treatment of adults with asthma
J Allergy Clin Immunol
(2001) - et al.
Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5 and STAT6-dependent mechanism
Gastroenterology
(2003)
There are more references available in the full text version of this article.
Cited by (47)
Broad transcriptional response of the human esophageal epithelium to proton pump inhibitors
2021, Journal of Allergy and Clinical ImmunologyOmeprazole inhibits IgE-mediated mast cell activation and allergic inflammation induced by ingested allergen in mice
2020, Journal of Allergy and Clinical ImmunologyCitation Excerpt :An equal volume of complete media was added to the activated omeprazole to neutralize the pH before adding it to cell cultures. Cells were treated with omeprazole at a final concentration of 50 μM as previously reported.21-23 Drug vehicle (dimethyl sulfoxide) was prepared in the same manner, including acidification and neutralization, at equal volumes.
A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors
2020, Journal of Allergy and Clinical ImmunologyInteractions between gastro-oesophageal reflux disease and eosinophilic oesophagitis
2015, Best Practice and Research: Clinical GastroenterologyProton pump inhibitor treatment decreased duodenal and esophageal eosinophilia in a case of eosinophilic gastroenteritis
2015, Allergology International
Supported by Fondo Europeo Desarrollo Regional (FEDER) Funds, Spanish public funds Fondo de Investigacion Sanitaria 06/1431, and Junta de Extremadura PRI06A035 and SCSS0744. M.D.R. was supported by Subdireccion General de Investigacion Sanitaria CA06/0110.
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.
Copyright © 2009 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.